Pag. 63-65 [prev][index][next]
PLiposomal doxorubicin: emergent data in lymphoproliferative disease
L. Rigacci
Hematology Department Azienda Ospedaliera and University of Florence, Italy
Doxorubicin is classified as an anthracycline antibiotic. Doxorubicin is an effective antineoplastic agent and is widely used as one of the components in multiple-drug chemotherapy in the treatment of Hodgkin’s lymphoma, aggressive non Hodgkin’s lymphomas, acute lymphoblastic leukaemia, metastatic breast carcinoma, ovarian carcinoma, lung carcinoma and sarcoma. However, the clinical utility of the drug is limited by irreversible cardiomiopathy. Doxorubicin-associated myocardial damage is cumulative, dose-related, progressive and may lead to congestive heart failure (CHF).1 The incidence of CHF varies as the results of differences in study populations, treatment regimens, and the duration of follow-up.